MARIETTA, Ga., Dec. 21, 2010 /PRNewswire-FirstCall/ — MiMedx
Group, Inc. (OTC Bulletin Board:
MDXG), an integrated developer, manufacturer and marketer of
patent protected biomaterial-based products, announced today that
it has signed a definitive agreement to acquire Surgical Biologics,
a leader in the development of tissue processing techniques for
creating implants for a variety of surgical indications from amnion
membranes.
Privately held Surgical Biologics was founded in early 2006 and
is headquartered in Kennesaw, Georgia. In its five year history,
Surgical Biologics has established its reputation as a pioneer in
the development of the latest advances in processing amniotic
membrane tissues that provide safe, reliable and effective
implants. Through Purion®, its proprietary tissue processing
technology which produces an implant that is minimally manipulated,
Surgical Biologics has differentiated itself, and its tissues are
in over 30,000 implants. The Purion® process follows strict
guidelines for allograft processing established by the Food and
Drug Administration (“FDA”) and the American Association of Tissue
Banks (“AATB”).
The human amniotic membrane comprises the innermost layer of the
placenta, and lines the amniotic cavity. The amniotic tissue
processed by Surgical Biologics is donated by mothers who have
scheduled Cesarean sections. Each donor is screened and tested in
accordance with FDA regulations and AATB standards.
Parker H. “Pete” Petit, MiMedx Chairman and Chief Executive
Officer, stated, “We welcome Surgical Biologics and its founders,
John Daniel and Randall Spencer, to our organization. John and
Randall are well known in the area of tissue processing, and they
bring extensive expertise and experience to MiMedx Group. They will
be key members of our management team. We are excited about the
benefits we will attain through the com
‘/>”/>
SOURCE
